The hypermethylation of the CDKN2A promoter occurs in >50% of non-invasive IPMNs and IPMNs with associated carcinoma, but methylation is not a common inactivation mechanism for other pancreatic cancer driver genes such as TP53 and SMAD4 [30,31]. The gene discussed is SMAD4; the disease is familial pancreatic carcinoma.